Celldex Shares Plunge 7% Following Decision to Discontinue Barzolvolimab Development

Key Facts

In a move reflecting the high-stakes nature of the biotech sector, Celldex Therapeutics has decided to entirely discontinue the development of barzolvolimab for prurigo nodularis. This decisive action follows Phase 2 trial results where the treatment failed to meet its primary endpoint of itch improvement at Week 12. According to reports, the failure to satisfy key secondary objectives led management to scrap the program altogether rather than pursuing further reviews, triggering a sharp investor exit.

This development exerts significant operational pressure on the company, as the termination of lead drug candidates typically results in the loss of major growth catalysts. Per market data, CLDX shares plunged by more than 7% in extended trading on Tuesday following the announcement. This sell-off follows a previous close of $35.42 on July 20, 2026, signaling a radical reassessment by the market of the company's future commercial pipeline and valuation.

Looking at price levels, CLDX stood at $35.42 (close July 20, 2026) before the after-hours drop, which is expected to push the stock well below its recent support at $35.29. With the economic calendar showing no major sector catalysts over the next seven days, traders will focus on management's strategy for reallocating R&D resources. Market sentiment remains bearish as investors look for a new price floor following the loss of this key clinical program.